Join Growin Stock Community!

Smith & nephew plcSNN.US Overview

US StockHealthcare
(No presentation for SNN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SNN AI Insights

SNN Overall Performance

SNN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SNN Recent Performance

-5.05%

Smith & nephew plc

0.05%

Avg of Sector

-0.31%

S&P500

SNN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SNN Key Information

SNN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SNN Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Price of SNN

SNN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SNN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.13
PE Ratio (TTM)
33.24
Forward PE
-
PS Ratio (TTM)
2.63
PB Ratio
2.81
Price-to-FCF
19.56
METRIC
VALUE
vs. INDUSTRY
Gross Margin
70.04%
Net Margin
8.27%
Revenue Growth (YoY)
5.83%
Profit Growth (YoY)
5.39%
3-Year Revenue Growth
4.74%
3-Year Profit Growth
4.92%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.13
PE Ratio (TTM)
33.24
Forward PE
-
PS Ratio (TTM)
2.63
PB Ratio
2.81
Price-to-FCF
19.56
Gross Margin
70.04%
Net Margin
8.27%
Revenue Growth (YoY)
5.83%
Profit Growth (YoY)
5.39%
3-Year Revenue Growth
4.74%
3-Year Profit Growth
4.92%

  • When is SNN's latest earnings report released?

    The most recent financial report for Smith & nephew plc (SNN) covers the period of 2025Q2 and was published on 2025/06/28. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SNN's short-term business performance and financial health. For the latest updates on SNN's earnings releases, visit this page regularly.

  • Where does SNN fall in the P/E River chart?

    According to historical valuation range analysis, Smith & nephew plc (SNN)'s current price-to-earnings (P/E) ratio is 37.79, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of SNN?

    According to the latest financial report, Smith & nephew plc (SNN) reported an Operating Profit of 434.89M with an Operating Margin of 14.56% this period, representing a growth of 32.59% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is SNN's revenue growth?

    In the latest financial report, Smith & nephew plc (SNN) announced revenue of 2.99B, with a Year-Over-Year growth rate of 5.69%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does SNN have?

    As of the end of the reporting period, Smith & nephew plc (SNN) had total debt of 3.45B, with a debt ratio of 0.32. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does SNN have?

    At the end of the period, Smith & nephew plc (SNN) held Total Cash and Cash Equivalents of 676M, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does SNN go with three margins increasing?

    In the latest report, Smith & nephew plc (SNN) achieved the “three margins increasing” benchmark, with a gross margin of 70.62%%, operating margin of 14.56%%, and net margin of 9.9%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess SNN's profit trajectory and future growth potential.

  • Is SNN's EPS continuing to grow?

    According to the past four quarterly reports, Smith & nephew plc (SNN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.68. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SNN?

    Smith & nephew plc (SNN)'s Free Cash Flow (FCF) for the period is 259.32M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 292.91% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of SNN?

    The latest valuation data shows Smith & nephew plc (SNN) has a Price-To-Earnings (PE) ratio of 37.79 and a Price/Earnings-To-Growth (PEG) ratio of 0.24. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.